Back
to home » Treatment News » Top Stories
 August 31, 2010
|
Kaletra Monotherapy Failure Predicted by HIV Levels in the Brain
Not only was Kaletra (lopinavir plus ritonavir) monotherapy inferior to standard three-drug treatment in people with HIV, but rising HIV levels in the cerebrospinal fluid (CSF) were tied to treatment failure. These results, published online August 26 in AIDS, also revealed that the people most likely to experience treatment failure while on monotherapy were those whose CD4 count had ever fallen below 200.
|
|
|
August 30, 2010
|
Genetic Factor Strongly Predicts Response to Hep C Therapy
HIV-positive people with an inherited mutation in a specific gene are far more likely to respond to hepatitis C virus (HCV) therapy than people without the mutation, according to a study published online August 30 in the journal Clinical Infectious Diseases. Testing for the gene could help identify those most—and least—likely to benefit from HCV treatment.
|
|
|
August 27, 2010
|
High Level of Bone Loss in Men Recently Infected With HIV
Levels of bone mineral loss were far higher in a small group of men who had been recently infected with HIV than is typically seen in HIV-negative men of similar age and demographics, according to a study published in the September 10 issue of AIDS.
|
|
|
| August 25, 2010
|
August 24, 2010
|
Long-Term Imiquimod Treatment Helps Clear High-Grade Anal Lesions
Long-term treatment with a topical immune-stimulating cream called Aldara (imiquimod), approved for the treatment of external genital warts, may also improve or clear high-grade lesions inside the anuses of men living with HIV and may potentially reduce the risk of cancer. This is the conclusion of a study published online August 19 in the journal AIDS.
|
|
|
August 23, 2010
|
Two Approved Cancer Drugs Fight HIV
A combination of two U.S. Food and Drug Administration (FDA)-approved cancer drugs effectively reduced HIV replication in the lab, according to a study published in the September issue of the Journal of Virology.
|
|
|
August 20, 2010
|
New HIV Microbicide Candidate Has Unique Properties
An experimental HIV entry inhibitor might be particularly well suited for use as a preventive microbicide—due to the area of the virus it targets and its potential to avoid being quickly broken down by the body. Scientists announced their findings about the drug, which is still in early development, on August 18 in an online article in the journal Virology.
|
|
|
August 19, 2010
|
New Strategy Could Eradicate Latent HIV-Infected Cells
Researchers report that they have taken the first step toward killing cells that are latently infected with HIV—cells that serve as a reservoir of persistent HIV reproduction and that current antiretroviral (ARV) drugs can’t reach. Their findings have been accepted by the open-access journal AIDS Research and Therapy.
|
|
|
| August 18, 2010
|
August 17, 2010
|
PTSD Symptoms Common Among People With HIV
One third of HIV-positive men participating in a U.K. survey met the criteria for an HIV-related diagnosis of post-traumatic stress disorder (PTSD), according to a report published in the August 16 issue of AIDS Patient Care and STDs. A particularly notable finding was that starting antiretroviral therapy can be a PTSD trigger among people living with HIV.
|
|
|
August 16, 2010
|
Large Review of Tenofovir Studies Finds Modest Impact on Kidneys
An analysis of 17 studies, involving nearly 11,000 patients, found that while tenofovir (found in Viread, Truvada and Atripla) can negatively impact kidney function, the long-term clinical impact is quite modest. This analysis was published in the September 1 issue of the journal Clinical Infectious Diseases.
|
|
|
August 13, 2010
|
New Study and Editorial Highlight the Potential of Test and Treat
A new study and an accompanying editorial published in the August 14 issue of The Lancet highlight the potential to reduce ongoing HIV transmission in a community simply through aggressive testing and treatment of HIV-positive people with antiretroviral (ARV) drugs.
|
|
|
August 12, 2010
|
Nasal Antibiotic Might Reduce Staph Infections
A five-day course of a nasal antibiotic ointment every month showed a trend toward protection from Staphylococcus aureus (staph) infections, according to a study published online August 11 in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
| August 11, 2010
|
August 10, 2010
|
Telaprevir-Based Regimen as Good for Hep C Over 24 Weeks as 48 Weeks
A treatment regimen containing the experimental hepatitis C virus (HCV) antiviral telaprevir can cure HCV after 24 weeks of treatment—without requiring a full 48-week course of therapy—in people with HCV genotype 1 who have undetectable virus levels after 4 and 12 weeks of therapy. These early results from a clinical trial conducted by Vertex Pharmaceuticals were reported in a press release from the company.
|
|
|
August 09, 2010
|
Few HIV-Positive People Who Need Aspirin Are Taking It
Fewer than 10 percent of people with HIV who should take aspirin to prevent a heart attack actually take the medication, according to a small study published in the August 15 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
August 06, 2010
|
Cause of Higher Risk of Heart Disease in HIV Remains Unexplained, But Tenofovir May Be Protective
Despite a new analysis of data from the Fat Redistribution and Metabolic Change in HIV (FRAM) study, it’s still unclear which HIV-specific factors—HIV infection itself or the antiretrovirals (ARVs) used to treat it—contribute to an increased risk of heart disease in people living with the virus. Interestingly, the FRAM report, published online July 27 in the journal AIDS, stated that tenofovir—found in Viread, Truvada and Atripla—appears to be modestly associated with a lower risk of carotid artery thickness, a predictor of cardiovascular disease (CVD).
|
|
|
August 05, 2010
|
Some People With Low CD4 Counts Can Safely Stop Taking PCP Prophylaxis
Some people with CD4 counts under 200 can safely stop taking preventive treatment (prophylaxis) for Pnuemocystis jiroveci pneumonia (PCP), provided that their HIV levels are well controlled by antiretroviral (ARV) medication. These data were published in the September 1 issue of the journal Clinical Infectious Diseases.
|
|
|
August 04, 2010
|
Late HIV Diagnosis Is Substantially Higher in People Over 50
People age 50 and older are nearly 2.5 times more likely to be diagnosed late with HIV than younger adults, according to a study published in the August 24 issue of AIDS. What’s more, older people who are diagnosed late are 14 times more likely to die prematurely than people who are diagnosed promptly after infection.
|
|
|
August 03, 2010
|
More Frequent Screening of HIV-Positive MSM Increases Early Syphilis Diagnoses
Four times as many asymptomatic syphilis cases in HIV-positive men who have sex with men (MSM) could be found if providers tested for the disease more frequently, according to a study published online July 30 in the Journal of Acquired Immune Deficiency Syndromes. The study also suggests that more frequent testing could reduce the prevalence of syphilis.
|
|
|
| August 02, 2010
|
|
|
|
 |
|
